Analyst Price Targets — SPRB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 17, 2026 11:04 am | — | Guggenheim | $104.00 | $52.64 | TheFly | Spruce Biosciences price target lowered to $104 from $123 at Guggenheim |
| June 16, 2026 10:40 am | Debjit Chattopadhyay | Guggenheim | $123.00 | $49.91 | TheFly | Spruce Biosciences initiated with a Buy at Guggenheim |
| June 1, 2026 10:08 am | — | H.C. Wainwright | $150.00 | $51.27 | TheFly | Spruce Biosciences price target lowered to $150 from $200 at H.C. Wainwright |
| April 27, 2026 12:05 pm | Albert Lowe | Craig-Hallum | $140.00 | $55.63 | TheFly | Spruce Biosciences initiated with a Buy at Craig-Hallum |
| December 23, 2025 11:26 am | — | Oppenheimer | $283.00 | $82.82 | TheFly | Spruce Biosciences initiated with an Outperform at Oppenheimer |
| November 11, 2025 10:52 am | — | JMP Securities | $259.00 | $115.61 | TheFly | Spruce Biosciences price target raised to $259 from $254 at Citizens JMP |
| October 28, 2025 8:41 am | — | JMP Securities | $254.00 | $123.02 | TheFly | Spruce Biosciences upgraded to Outperform from Market Perform at Citizens JMP |
| October 21, 2025 6:38 pm | — | Leerink Partners | $160.00 | $134.00 | StreetInsider | Spruce Biosciences, Inc. (SPRB) PT Raised to $160 at Leerink PartnersMember Login |
Latest News for SPRB
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disor
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the launch of MPS3BStudy.com, a dedicated online resource for families and caregivers of children with Sanfilippo Syndrome Type B (MPS IIIB). The website…
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB) (“Spruce”), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has completed two pre-BLA meetings with the U.S. Food and Drug Administration (FDA) that support the company's plan to submit a BLA for…
Spruce Biosciences, Inc. (Nasdaq: SPRB) a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disord
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2026, and provided corporate updates. “The second quarter was a period of significant execution as…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SPRB.
U.S. House Trading
No House trades found for SPRB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.